Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.69 |
| ▸ | MLNR | O43193 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | NPY1R | P25929 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258716 | 1.00 | ESR1 (0.69) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL16701296 | 1.00 | ESR1 (0.69) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Bromide SCHEMBL3639072 | 0.99 | ESR1 (0.68) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL3801089 | 0.93 | ESR1 (0.61) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL3713135 | 0.89 | ESR1 (0.63) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL23350302 | 0.85 | ESR1 (0.66) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL19235625 | 0.82 | ESR1 (0.73) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL9885582 | 0.82 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL3774585 | 0.82 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL3774592 | 0.82 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424839-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | Glenmark Generics Limited (IN) | 2012-03-07 | — | — | EP | claimed |
| WO-2010125578-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | GLENMARK GENERICS LIMITED (IN) | 2010-11-04 | — | — | WO | claimed |
| EP-2164836-A2 | METHOD FOR THE PREPARATION OF LASOFOXIFENE AND CRYSTALLINE INTERMEDIATES USED THEREIN | Zentiva, k.s. (CZ) | 2010-03-24 | — | — | EP | claimed |
| WO-2008145075-A2 | METHOD FOR THE PREPARATION OF LASOFOXIFENE AND CRYSTALLINE INTERMEDIATES USED THEREIN | ZENTIVA, A.S. (CZ) | 2008-12-04 | — | — | WO | claimed |
| EP-3515424-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | Repros Therapeutics Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018058032-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | REPROS THERAPEUTICS INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| EP-2914294-A1 | TRANS-CLOMIPHENE FOR USE IN CANCER THERAPY | Repros Therapeutics Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014070523-A1 | TRANS-CLOMIPHENE FOR USE IN CANCER THERAPY | REPROS THERAPEUTICS INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2424839-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | Glenmark Generics Limited (IN) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125578-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | GLENMARK GENERICS LIMITED (IN) | 2010-11-04 | — | — | WO | disclosed |
| EP-2211848-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | Repros Therapeutics Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010054248-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME AND DIABETES MELLITUS TYPE 2 | REPROS THERAPEUTICS INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20050171189-A1 | Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a mehtod for effective purification of racemic lasofoxifene | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171189-A1 | Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a mehtod for effective purification of racemic lasofoxifene | GPER1, OPRD1, ESR1 | ESR1 3/4885ESR2 5/4885MLNR 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.